Literature DB >> 8501230

Epidemiologic analysis and genotypic characterization of a nosocomial outbreak of vancomycin-resistant enterococci.

J F Boyle1, S A Soumakis, A Rendo, J A Herrington, D G Gianarkis, B E Thurberg, B G Painter.   

Abstract

We are reporting on a nosocomial outbreak of 213 cases of vancomycin-resistant enterococcus infection involving 2,812 enterococcal isolates from patients over a period of 36 months. In 1990, the Enterococcus faecium vancomycin susceptibility rate was found to be 85.7% (36 of 42 cases), and an incidence of 10.9% (42 of 383) was noted. The 1991 data showed E. faecium with a vancomycin susceptibility rate of 61.8% (110 of 178) and an incidence of 26.0% (178 of 684). Subsequently, in 1992, the incidence of E. faecium increased to 34.0% (599 of 1,745), with a decreased vancomycin susceptibility rate of 25.8% (155 of 599). The E. faecalis vancomycin susceptibility rate remained near 97% (1,768 of 1,823) over the 36-month period. Of 115 vancomycin-resistant enterococcus (VRE) clinical isolates identified by the MicroScan MIC Combo-6 panels (Baxter Healthcare, Sacramento, Calif.), the agar dilution method indicated the resistance rate to be 92.3% (106 of 115) (high level), 3.5% (4 of 115) midlevel, and 3.5% (4 of 115) (low level). Genotypic characterization of 32 different VRE isolates by field-inversion gel electrophoresis demonstrated 19 dissimilar restriction endonuclease patterns, with 9 patterns associated with VRE quinolone resistance. Statistical analysis of case-control data for 32 patients with VRE infections indicated a positive association with intrabdominal surgical procedures (odds ratio, 24.12), multidrug therapy (odds ratio, 37.80), preexposure to vancomycin (odds ratio, 20.21), and death (odds ratio, 17.50).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8501230      PMCID: PMC262918          DOI: 10.1128/jcm.31.5.1280-1285.1993

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  28 in total

Review 1.  Emergence of Enterococcus as a significant pathogen.

Authors:  R C Moellering
Journal:  Clin Infect Dis       Date:  1992-06       Impact factor: 9.079

2.  Intrahospital spread of a single gentamicin-resistant, beta-lactamase-producing strain of Enterococcus faecalis in Argentina.

Authors:  B E Murray; H A Lopardo; E A Rubeglio; M Frosolono; K V Singh
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

3.  Detection of vancomycin resistance in Enterococcus species.

Authors:  B M Willey; B N Kreiswirth; A E Simor; G Willaims; S R Scriver; A Phillips; D E Low
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

4.  Mechanisms of clinical resistance to fluoroquinolones in Enterococcus faecalis.

Authors:  N Nakanishi; S Yoshida; H Wakebe; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

5.  Inducible carboxypeptidase activity in vancomycin-resistant enterococci.

Authors:  L Gutmann; D Billot-Klein; S al-Obeid; I Klare; S Francoual; E Collatz; J van Heijenoort
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

6.  DNA fingerprinting of Enterococcus faecium by pulsed-field gel electrophoresis may be a useful epidemiologic tool.

Authors:  A G Miranda; K V Singh; B E Murray
Journal:  J Clin Microbiol       Date:  1991-12       Impact factor: 5.948

7.  Infections due to beta-lactamase-producing, high-level gentamicin-resistant Enterococcus faecalis.

Authors:  V D Wells; E S Wong; B E Murray; P E Coudron; D S Williams; S M Markowitz
Journal:  Ann Intern Med       Date:  1992-02-15       Impact factor: 25.391

8.  Emergence and nosocomial transmission of ampicillin-resistant enterococci.

Authors:  J M Boyce; S M Opal; G Potter-Bynoe; R G LaForge; M J Zervos; G Furtado; G Victor; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

9.  High-level resistance to gentamicin in clinical isolates of enterococci.

Authors:  B D Mederski-Samoraj; B E Murray
Journal:  J Infect Dis       Date:  1983-04       Impact factor: 5.226

10.  Vancomycin therapy in patients with impaired renal function: a nomogram for dosage.

Authors:  R C Moellering; D J Krogstad; D J Greenblatt
Journal:  Ann Intern Med       Date:  1981-03       Impact factor: 25.391

View more
  37 in total

1.  Molecular epidemiology of vancomycin-resistant Enterococcus faecium in a large urban hospital over a 5-year period.

Authors:  W E Bischoff; T M Reynolds; G O Hall; R P Wenzel; M B Edmond
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

Review 2.  Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci.

Authors:  Stephan Harbarth; Sara Cosgrove; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

Review 3.  Vancomycin-resistant enterococci.

Authors:  Y Cetinkaya; P Falk; C G Mayhall
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

4.  Vancomycin-resistant enterococci (VRE) in Canada - Results of the Canadian Nosocomial Infection Surveillance Program 1996 VRE point prevalence surveillance project.

Authors:  M E Ofner-Agostini; J Conly; S Paton; A Kureishi; L Nicolle; M Mulvey; W Johnson; L Johnston
Journal:  Can J Infect Dis       Date:  1997-03

5.  A population pharmacokinetic model for vancomycin in pediatric patients and its predictive value in a naive population.

Authors:  P Lamarre; D Lebel; M P Ducharme
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

Review 6.  Antimicrobial stewardship programs in health care systems.

Authors:  Conan MacDougall; Ron E Polk
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

7.  A 24-hour screening protocol for identification of vancomycin-resistant Enterococcus faecium.

Authors:  Steven J Drews; Grant Johnson; Farhad Gharabaghi; Margaret Roscoe; Anne Matlow; Raymond Tellier; Susan E Richardson
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

8.  Are clinical laboratories in California accurately reporting vancomycin-resistant enterococci?

Authors:  J Rosenberg; F C Tenover; J Wong; W Jarvis; D J Vugia
Journal:  J Clin Microbiol       Date:  1997-10       Impact factor: 5.948

9.  Random amplified polymorphic DNA typing versus pulsed-field gel electrophoresis for epidemiological typing of vancomycin-resistant enterococci.

Authors:  N Barbier; P Saulnier; E Chachaty; S Dumontier; A Andremont
Journal:  J Clin Microbiol       Date:  1996-05       Impact factor: 5.948

10.  Selective isolation of vancomycin-resistant enterococci.

Authors:  K G van Horn; C A Gedris; K M Rodney
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.